坦度螺酮与丁螺环酮治疗广泛性焦虑症的系统评价

目的 系统评价坦度螺酮与丁螺环酮治疗广泛性焦虑症的疗效与安全性。方法 计算机检索PubMed、中国期刊全文数据库（CNKI）、中国生物医学文献数据库（CBM）、万方数据库、中文科技期刊全文数据库（VIP），收集坦度螺酮与丁螺环酮治疗广泛性焦虑症的随机对照研究（RCT），检索时限为2000年1月至2016年6月，并追溯纳入研究的参考文献。2位研究者按照纳入与排除标准独立筛选文献、提取资料和评价文献质量后，用RevMan5.0软件对各效应指标进行Meta分析。结果 共纳入7篇RCT，合计615例广泛性焦虑症患者。Meta分析结果显示：坦度螺酮（试验组）与丁螺环酮（对照组）在显效率P=0.34，OR=1.19，95% Cl（0.83～1.69）]与HAMA评分方面P=0.80，MD=-0.08，95% Cl（-0.72～0.56）]差异无统计学意义（P>0.05）；2组头晕、口干、便秘、失眠、食欲减退、恶心发生率差异无统计学意义（P>0.05）。结论 坦度螺酮与丁螺环酮治疗广泛性焦虑症疗效相当，常见不良反应发生风险相似。

Systematic review of tandospirone and buspirone in treatment of patients with generalized anxiety disorder

Objective To evaluate the therapeutic effect and safety of tandospirone and buspirone in the treatment of generalized anxiety disorder. Methods The clinical control study of tandospirone and buspirone in the treatment of generalized anxiety disorder was earched by PubMed, CBM, CNKI, VIP, and Wanfang Data, with deadline from January 2000 to June 2016. Meta-analysis was carried out using RevMan5.0 software to each effect index. Results A total of seven RCTs were included involving 615 patients were identified. Meta-analysis showed that the significant efficiency rateP=0.34, OR=1.19, 95%CI (0.83~1.69)] and HAMAP=0.80, MD=-0.08, 95%CI (-0.72~0.56)] of tandospirone and buspirone had no significant difference. Two groups of adverse drug reactions, dizzy, dry, constipine, insomnia, anorexia, and nausea had no significant difference (P>0.05). Conclusion The efficacy and adverse reaction of tandospirone and buspirone in the treatment of generalized anxiety disorder are fairly.